The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1995-12-05

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1073/PNAS.92.25.11746PMID 8524841PMCID PMC40479
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transcription factor ATF2 regulation by the JNK signal transduction pathway

  1995cited by this paper
• Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs.

  1995cited by this paper
• Transforming G Protein-coupled Receptors Potently Activate JNK (SAPK)

  1995cited by this paper
• Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2.

  1995cited by this paper
• Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.

  1995cited by this paper
• The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway.

  1995cited by this paper
• Transcriptional regulation by extracellular signals: mechanisms and specificity.

  1995cited by this paper
• Stress-activated protein kinases bind directly to the delta domain of c-Jun in resting cells: implications for repression of c-Jun function.

  1995cited by this paper
• Case control study of chronic fatigue in pediatric patients.

  1995cited by this paper
• Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

  1995cited by this paper
• Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms

  1995cited by this paper
• Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

  1995cited by this paper
• Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.

  1994cited by this paper
• The stress-activated protein kinase subfamily of c-Jun kinases

  1994cited by this paper
• Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1

  1994cited by this paper
• JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.

  1994cited by this paper
• Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway

  1994cited by this paper
• v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element

  1994cited by this paper
• MAPKs: new JNK expands the group.

  1994cited by this paper
• Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth

  1994cited by this paper
• Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway.

  1994cited by this paper
• A temperature sensitive p210 BCR‐ABL mutant defines the primary consequences of BCR‐ABL tyrosine kinase expression in growth factor dependent cells.

  1994cited by this paper
• Ras-dependent growth factor regulation of MEK kinase in PC12 cells.

  1994cited by this paper
• Cellular interactions of CRKL, and SH2-SH3 adaptor protein.

  1994cited by this paper
• Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.

  1994cited by this paper
• Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun

  1994cited by this paper
• Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK.

  1994cited by this paper
• Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases.

  1994cited by this paper
• Differential complementation of Bcr-Abl point mutants with c-Myc.

  1994cited by this paper
• JNK is involved in signal integration during costimulation of T lymphocytes.

  1994cited by this paper
• SH2/SH3 signaling proteins.

  1994cited by this paper
• An actin‐binding function contributes to transformation by the Bcr‐Abl oncoprotein of Philadelphia chromosome‐positive human leukemias.

  1993cited by this paper
• Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins.

  1993cited by this paper
• Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of gamma-interferon receptors.

  1993cited by this paper
• A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins

  1993cited by this paper
• Reconstitution of the Raf-1—MEK—ERK Signal Transduction Pathway In Vitro

  1993cited by this paper
• Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.

  1993cited by this paper
• Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation.

  1993cited by this paper
• BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

  1993cited by this paper
• Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.

  1993cited by this paper
• Activation of extracellular signal‐regulated kinase, ERK2, by p21ras oncoprotein.

  1992cited by this paper
• The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.

  1991cited by this paper
• BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias

  1991cited by this paper
• Trans-dominant negative mutants of Fos and Jun.

  1990cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• The viral and cellular forms of the Abelson (abl) oncogene.

  1988cited by this paper
• The molecular genetics of Philadelphia chromosome-positive leukemias.

  1988cited by this paper
• Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor.

  1987cited by this paper

• Результаты лечения больных с хроническим миелоидным лейкозом в Кыргызской Республике с применением ингибиторов тирозинкиназ разных поколений

  2025cites this paper
• KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia

  2025cites this paper
• Expression profiles of miR-411 and SPRY4 as indicators of disease progression and treatment in chronic myelogenous leukemia

  2025cites this paper
• Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring

  2024cites this paper
• A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia

  2023cites this paper
• The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors

  2023cites this paper
• A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia

  2023cites this paper
• Ectopic expression of Nav1.7 in spinal dorsal horn neurons induced by NGF contributes to neuropathic pain in a mouse spinal cord injury model

  2023cites this paper
• Profiling of miRNAs and their interfering targets in peripheral blood mononuclear cells from patients with chronic myeloid leukaemia

  2023cites this paper
• Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

  2022cites this paper
• Generation of TRIM28 Knockout K562 Cells by CRISPR/Cas9 Genome Editing and Characterization of TRIM28-Regulated Gene Expression in Cell Proliferation and Hemoglobin Beta Subunits

  2022cites this paper
• International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms

  2022cites this paper
• MolHyb: A Web Server for Structure-Based Drug Design by Molecular Hybridization

  2022cites this paper
• DP from Euphorbia fischeriana S. mediated apoptosis in leukemia cells via the PI3k/Akt signaling pathways.

  2021cites this paper
• The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib

  2021cites this paper
• Current status and novel strategy of CML

  2021cites this paper
• Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia

  2021cites this paper
• Betulinic acid restores imatinib sensitivity in BCR‐ABL1 kinase−independent, imatinib‐resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation

  2020cites this paper
• E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer

  2020cites this paper
• Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

  2020cites this paper
• The Role of JAK2 Gene in Imatinib-Resistant Chronic Myeloid Leukemia: A Review

  2020cites this paper
• Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: Single‐center experience

  2020cites this paper
• Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

  2020cites this paper
• Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling

  2019cites this paper
• A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

  2019cites this paper
• Chronic myelogenous leukemia stem cells require cell-autonomous pleiotrophin signaling.

  2019cites this paper
• Co-activation of WT1 and AP-1 proteins on WT1 gene promoter to induce WT1 gene expression in K562 cells.

  2019cites this paper
• USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia

  2019cites this paper
• Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening

  2019cites this paper
• miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2.

  2018cites this paper
• Mitogen Activated Protein Kinases (MAPK), Ionising Radiation and Transcription Regulation

  2018cites this paper
• Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

  2018cites this paper
• BROCKMAN: deciphering variance in epigenomic regulators by k-mer factorization

  2018cites this paper
• BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells

  2018cites this paper
• MAPK/c-Jun signaling pathway contributes to the upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL induced by Epstein-Barr virus-encoded BARF1 in gastric carcinoma cells

  2018cites this paper
• Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

  2018cites this paper
• Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia

  2017cites this paper
• Investigation of the role of bone marrow stromal cells in the microenvironment of acute myeloid leukaemia

  2017cites this paper
• Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia

  2017cites this paper
• Chronic myeloid leukemia for general physicians : Not so alien anymore

  2017cites this paper
• Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways

  2017cites this paper
• Deciphering variance in epigenomic regulators by k-mer factorization

  2017cites this paper
• Targeting MUC1 and JNK by RNA interference and inhibitor inhibit the development of hepatocellular carcinoma

  2017cites this paper
• Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.

  2017cites this paper
• The NCK and ABI adaptor genes in catfish and their involvement in ESC disease response

  2017influential citation
• Reduced risk of apoptosis: mechanisms of stress responses

  2017cites this paper
• Treating early in the disease course: lessons from the CML model

  2017cites this paper
• Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization

  2017cites this paper
• Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives

  2017cites this paper
• CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

  2016cites this paper
• Rôle de la signalisation calcique dans la leucémie myéloïde chronique

  2016cites this paper
• Chronic myeloid leukemia: First‐line drug of choice

  2016cites this paper
• In vivo genetic dissection of tumor growth and the Warburg effect

  2016cites this paper
• Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

  2016cites this paper
• CME Information: Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy and monitoring

  2016cites this paper
• Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer

  2016cites this paper
• Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development

  2016cites this paper
• Characterization of Genomic Events Other than Ph and Evaluation of Prognostic Influence on Imatinib in Chronic Myeloid Leukemia (CML): A Study on 1449 Patients from India

  2016cites this paper
• Chromosomal Translocations and Genome Rearrangements in Cancer

  2015cites this paper
• Targeted Therapies in Chronic Myeloid Leukemia

  2015cites this paper
• Chronic Myeloid Leukaemia

  2015cites this paper
• Selecting the Best Frontline Treatment in Chronic Myeloid Leukemia

  2015cites this paper
• Chromosomal Translocations and Gene Rearrangements in Acute Lymphoblastic Leukaemia

  2015cites this paper
• Systematic proteomic analysis of oxygen mediated DNA damage

  2015cites this paper
• Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

  2015cites this paper
• Oxidative Stress Responses and NRF2 in Human Leukaemia

  2015cites this paper
• Systemic Review on Chronic Myeloid Leukemia: Therapeutic Targets, Pathways and Inhibitors

  2015cites this paper
• Inhibition of basal JNK activity by small interfering RNAs enhances cisplatin sensitivity and decreases DNA repair in T98G glioblastoma cells.

  2015cites this paper
• Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.

  2015cites this paper
• Cancer Preventive and Therapeutic Properties of Fruits and Vegetables Against Commonly Occurring Cancers in Humans

  2015cites this paper
• Role of MAPK and NF-κB signalling pathways in the regulation of the human GM-CSF gene in normal and leukaemic blood cells

  2015cites this paper
• Inhibition of Ras-mediated signaling pathways in CML stem cells

  2015cites this paper
• JNK signalling in cancer: in need of new, smarter therapeutic targets

  2014cites this paper
• CME Information: Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

  2014cites this paper
• Signal Transduction Therapies for Treatment of Chronic Leukemias

  2014cites this paper
• Roles of phosphorylated JNK in esophageal squamous cell carcinomas of kazakh ethnic

  2014cites this paper
• Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias

  2014cites this paper
• serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis Complementary functions of the antiapoptotic protein A1 and

  2013cites this paper
• Increased Cytoplasmic Localization of p27kip1 and Its Modulation of RhoA Activity during Progression of Chronic Myeloid Leukemia

  2013cites this paper
• Treatment options for tyrosine kinase inhibitor-resistant chronic myeloid leukemia

  2013cites this paper
• CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing

  2013cites this paper
• Increasing sensitivity to drugs in leukemias by modulation of microRNA expression

  2013influential citation
• mutant defective in transformation Bcl-2 expression restores the leukemogenic potential of a BCR/ABL

  2013cites this paper
• Impact of imatinib mesylate on SLC22A1 gene expression in chronic myeloid leukaemia cell line, K562

  2013cites this paper
• ATYPICAL CHRONIC MYELOID LEUKEMIA

  2013cites this paper
• JNK is a novel regulator of intercellular adhesion

  2013cites this paper
• Functional Modeling of Genes Upregulated in Chronic Myeloid Leukemia

  2013cites this paper
• Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.

  2013cites this paper
• Ponatinib—A Step Forward in Overcoming Resistance in Chronic Myeloid Leukemia

  2013cites this paper
• Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

  2013cites this paper
• New insights into biology of chronic myeloid leukemia: implications in therapy.

  2013cites this paper
• New roles of STAT5 factors in chronic myeloid leukemia cell maintenance

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.

  2013cites this paper
• Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series

  2013cites this paper
• Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.

  2013cites this paper
• Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia

  2013cites this paper
• LYMPHOID NEOPLASIA SOX 4 enables oncogenic survival signals in acute lymphoblastic leukemia

  2012cites this paper
• VALIDATION OF RS 9971 SINGLE NUCLEOTIDE POLYMORPHISM (SNP) IN BLOOD CANCER PATIENTS OF HYDERABAD – INDIA

  2012cites this paper
• Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

  2012cites this paper